Phase II Study of Yttrium-90-Ibritumomab Tiuxetan as Part of Reduced-Intensity Conditioning (with Melphalan, Fludarabine ± Thiotepa) for Allogeneic Transplantation in Relapsed or Refractory Aggressive B Cell Lymphoma: A GELTAMO Trial
Y-90 ibritumomab tiuxetan was used as a part of a reduced-intensity conditioning regimen phase II multicenter trial Conditioning regimen with radioimmunotherapy is safe and well tolerated The addition of radioimmunotherapy results in a long-term progression-free survival of 44% No significant toxicities related to Y-90 ibritumomab tiuxetan have been reported Our 46-month median follow-up is the longest reported in a radioimmunotherapy allogeneic stem cell transplantation trial